Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leader in stem cell
therapeutics, announced today that it will report its financial results
for the quarter ended June 30, 2008, on Thursday, August 7, 2008. C.
Randal Mills, Ph.D., President and Chief Executive Officer, and Richard
Hunt, Chief Financial Officer, will provide a company update and discuss
results via a webcast and conference call on Thursday, August 7, 2008 at
9:00 a.m. EDT.
To access the webcast, visit the Investor Relations section of the
company's website at http://investor.osiris.com/events.cfm.
Alternatively, callers may participate in the conference call by dialing
(877) 681-3373 (U.S. participants) or (719) 325-4877 (international
participants).
A replay of the conference call will be available approximately two
hours after the completion of the call through August 21, 2008. Callers
can access the replay by dialing (888) 203-1112 (U.S. participants) or
(719) 457-0820 (international participants). The audio replay passcode
is 1544354. To access a replay of the webcast, visit the Investor
Relations section of the company's website at http://investor.osiris.com/events.cfm.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a leading stem cell therapeutic company
focused on developing products to treat medical conditions in the
inflammatory, orthopedic and cardiovascular areas. Prochymal is being
evaluated in Phase III clinical trials for three indications, including
acute and steroid refractory Graft versus Host Disease and also Crohn's
disease, and is the only stem cell therapeutic currently designated by
FDA as both an Orphan Drug and Fast Track product. Osiris also has
partnered with Genzyme Corporation to develop Prochymal as a medical
countermeasure to nuclear terrorism and other radiological emergencies.
Furthermore, Prochymal is being developed for the repair of heart tissue
following a heart attack, the protection of pancreatic islet cells in
patients with type 1 diabetes, and the repair of lung tissue in patients
with chronic obstructive pulmonary disease. The Company’s
pipeline of internally developed biologic drug candidates under
evaluation also includes Chondrogen for arthritis in the knee. Osiris is
a fully integrated company, having developed capabilities in research,
development, manufacturing, and distribution of stem cell products.
Osiris has developed an extensive intellectual property portfolio to
protect the company's technology including 47 U.S. patents each having
one or more foreign counterparts. Osiris, Prochymal and Chondrogen are
registered trademarks of Osiris Therapeutics, Inc.
